CoChat
Sign Up
Cited by 170

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Immune-mediated drug-induced liver disease

Liu, Zhang-Xu, Kaplowitz, Neil·2002·Clinics in Liver Disease
DOI 10.1016/s1089-3261(02)00025-9
Open this paper in CoChat — free account

Abstract

Drug-induced immune-mediated hepatic injury is an adverse immune response against the liver that results in a disease with hepatitic, cholestatic, or mixed clinical features. Drugs such as halothane, tienilic acid, dihydralazine, and anticonvulsants trigger a hepatitic reaction, and drugs such as chlorpromazine, erythromycins, amoxicillin-calvulanic acid, sulfonamides and sulindac trigger a cholestatic or mixed reaction. Unstable metabolites derived from the metabolism of the drug may bind to cellular proteins or macromolecules, leading to a direct toxic effect on hepatocytes. Protein adducts formed in the metabolism of the drug may be recognized by the immune system as neoantigens. Immunocyte activation may then generate autoantibodies and cell-mediated immune responses, which in turn damage the hepatocytes. Cytochromes 450 are the major oxidative catalysts in drug metabolism, and they can form a neoantigen by covalently binding with the drug metabolite that they produce. Autoantibodies that develop are selectively directed against the particular cytochrome isoenzyme that metabolized the parent drug. The hapten hypothesis proposes that the drug metabolite can act as a hapten and can modify the self of the individual by covalently binding to proteins. The danger hypothesis proposes that the immune system only responds to a foreign antigen if the antigen is associated with a danger signal, such as cell stress or cell death. Most clinically overt adverse hepatic events associat…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1089-3261(02)00025-9

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 94

  1. Obermayer-Straub, 2000, Autoimmune hepatitis, J Hepatol, 32, 181, 10.1016/S0168-8278(00)80425-0 · DOI
  2. Manns, 1997, Cytochrome P450 and uridine triphosphate-glucuronosyltransferase: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease, Hepatology, 26, 1054, 10.1002/hep.510260438 · DOI
  3. Robin, 1997, Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis, J Hepatol, 26, 23, 10.1016/S0168-8278(97)82329-X · DOI
  4. Bissell, 2001, Drug-induced livery injury: mechanisms and test systems, Hepatology, 33, 1009, 10.1053/jhep.2001.23505 · DOI
  5. Kaplowitz, 2001, Drug-induced liver diseases: implications for drug development and regulation, Drug Saf, 24, 483, 10.2165/00002018-200124070-00001 · DOI
  6. Beaune, 1997, Immunotoxicity of the liver: adverse reactions to drugs, J Hepatol, 26, 37, 10.1016/S0168-8278(97)80495-3 · DOI
  7. Knowles, 2000, Idiosyncratic drug reactions: the reactive metabolite syndrome, Lancet, 356, 1587, 10.1016/S0140-6736(00)03137-8 · DOI
  8. Uetrecht, 1999, New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system, Chem Res Toxicol, 12, 387, 10.1021/tx980249i · DOI
  9. Kitteringham, 1990, Drug-protein conjugation and its immunological consequences, Drug Metabol Rev, 22, 87, 10.3109/03602539008991445 · DOI
  10. Matzinger, 1994, Tolerance, danger, and the extended family, Annu Rev Immunol, 12, 991, 10.1146/annurev.iy.12.040194.005015 · DOI
  11. Gordin, 1984, Adverse reactions to trimethoprin-sulfamethoxazole in patients with the acquired immunodeficiency syndrome, Ann Intern Med, 100, 495, 10.7326/0003-4819-100-4-495 · DOI
  12. Bourdi, 1994, Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-P4501A2 autoantibodies, Mol Pharmacol, 45, 1287, 10.1016/S0026-895X(25)10602-0 · DOI
  13. Bourdi, 1990, Anti-liver endoplasmic reticulum autoantibodies are directed against human liver cytochrome P-450 IA2. A specific marker of dihydralazine-induced hepatitis, J Clin Invest, 85, 1967, 10.1172/JCI114660 · DOI
  14. Beaune, 1994, Autoantibodies against cytochromes P450: role in human diseases, Adv Pharmacol, 30, 199, 10.1016/S1054-3589(08)60175-1 · DOI
  15. Vergani, 1980, Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis, N Engl J Med, 303, 66, 10.1056/NEJM198007103030202 · DOI
  16. Eliasson, 1996, Cytochrome P4502E1 is a cell surface autoantigen in halothane hepatitis, Mol Pharmacol, 50, 573, 10.1016/S0026-895X(25)09316-2 · DOI
  17. Loeper, 1993, Cytochromes P-450 on human hepatocyte plasma membrane. Recognition by several autoantibodies, Gastroenterology, 104, 203, 10.1016/0016-5085(93)90853-5 · DOI
  18. Loeper, 1990, Presence of functional cytochrome P-450 on isolated rat hepatocyte plasma membrane, Hepatology, 11, 850, 10.1002/hep.1840110521 · DOI
  19. Robin, 2000, Vesicular transport of newly synthesized cytochromes P4501A to the outside of rat hepatocyte plasma membranes, J Pharmacol Exp Ther, 294, 1063, 10.1016/S0022-3565(24)39172-4 · DOI
  20. Robin, 1996, Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera, J Clin Invest, 98, 1471, 10.1172/JCI118936 · DOI
  21. Satoh, 1987, An immunochemical approach to investigating the mechanism of halothane-induced hepatotoxicity, Prog Drug Metab, 10, 187
  22. Sakaguchi, 1984, Signal recognition particle is required for the co-translational insertion of cytochrome P450 into microsomal membranes, Proc Natl Acad Sci USA, 81, 3361, 10.1073/pnas.81.11.3361 · DOI
  23. Robin, 1995, Cytochrome P4502B follows a vesicular route to the plasma membrane in cultured rat hepatocytes, Gastroenterology, 108, 1110, 10.1016/0016-5085(95)90210-4 · DOI
  24. Haouzi, 2000, Cytochrome P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocytes, Hepatology, 32, 303, 10.1053/jhep.2000.9034 · DOI
  25. Yang, 1995, Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo, Proc Natl Acad Sci USA, 92, 7257, 10.1073/pnas.92.16.7257 · DOI
  26. Neuberger, 1989, Immune mechanism in tienilic acid associated hepatotoxicity, Gut, 30, 515, 10.1136/gut.30.4.515 · DOI
  27. Kita, 2001, The lymphoid liver: considerations on pathways to autoimmune injury, Gastroenterology, 120, 1485, 10.1053/gast.2001.22441 · DOI
  28. Abo, 1991, The appearance of T cells bearing self-reactive T cell receptor in the livers of mice injected with bacteria, J Exp Med, 174, 417, 10.1084/jem.174.2.417 · DOI
  29. Bendelac, 1997, Mouse CD1-specific NK1 T cells: development, specificity, and function, Annu Rev Immunol, 15, 535, 10.1146/annurev.immunol.15.1.535 · DOI
  30. Crispe, 1996, Strange brew: T cells in the liver, Immunol Today, 17, 522, 10.1016/S0167-5699(96)80906-6 · DOI
  31. Exley, 1997, Requirements for CD1d recognition by human invariant Vα 24+ CD4− CD8− T cells, J Exp Med, 186, 109, 10.1084/jem.186.1.109 · DOI
  32. Carnaud, 1999, Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells, J Immunol, 163, 4647, 10.4049/jimmunol.163.9.4647 · DOI
  33. Godfrey, 2000, NKT cells: facts, functions and fallacies, Immunol Today, 21, 573, 10.1016/S0167-5699(00)01735-7 · DOI
  34. Cui, 1997, Requirement for Vα 14 NKT cells in IL-12-mediated rejection of tumors, Science, 278, 1623, 10.1126/science.278.5343.1623 · DOI
  35. Kakimi, 2000, Natural killer T cell activation inhibits hepatitis B virus replication In vivo, J Exp Med, 192, 921, 10.1084/jem.192.7.921 · DOI
  36. Singh, 1999, Activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype, J Immunol, 163, 2373, 10.4049/jimmunol.163.5.2373 · DOI
  37. Toyabe, 1997, Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice, J Immunol, 159, 1537, 10.4049/jimmunol.159.3.1537 · DOI
  38. Kharasch, 1996, Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis, Lancet, 347, 1367, 10.1016/S0140-6736(96)91011-9 · DOI
  39. Satoh, 1985, Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes, J Pharmaocol Exp Ther, 233, 857, 10.1016/S0022-3565(25)22885-3 · DOI
  40. Bourdi, 1996, Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis, Chem Res Toxicol, 9, 1159, 10.1021/tx960083q · DOI
  41. Kitteringham, 1995, Detection of autoantibodies directed against human hepatic endoplasmic-reticulum in sera from patients with halothane-associated hepatitis, Br J Clin Pharmarcol, 40, 379, 10.1111/j.1365-2125.1995.tb04560.x · DOI
  42. Kenna, 1988, Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluroracetyl group derived from halothane, J Pharmacol Exp Ther, 245, 1103, 10.1016/S0022-3565(25)24104-0 · DOI
  43. Kenna, 1997, Immunoallergic drug-induced hepatitis: lessons from halothane, J Hepatol, 26, 5, 10.1016/S0168-8278(97)82327-6 · DOI
  44. Homberg, 1985, Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies, Hepatology, 5, 722, 10.1002/hep.1840050504 · DOI
  45. Homberg, 1984, A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid induced hepatitis, Clin Exp Immunol, 55, 561
  46. Zimmerman, 1984, Ticrynafen-associated hepatic injury: analysis of 340 cases, Hepatology, 4, 315, 10.1002/hep.1840040223 · DOI
  47. Beaune, 1987, Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug, Proc Natl Acad Sci USA, 84, 551, 10.1073/pnas.84.2.551 · DOI
  48. Lecoeur, 1996, Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P450 2C9, Mol Pharmacol, 50, 326, 10.1016/S0026-895X(25)09234-X · DOI
  49. Lecoeur, 1994, Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship with the type of hepatotoxicity: comparison with two directly hepatotoxic drugs, Chem Res Toxicol, 7, 434, 10.1021/tx00039a023 · DOI
  50. Lopez Garcia, 1994, Thiophene derivatives as new mechanism-based inhibitors of cytochrome P450: inactivation of yeast-expressed human liver P450 2C9 by tienilic acid, Biochemistry, 33, 166, 10.1021/bi00167a022 · DOI
  51. Lopez Garcia, 1993, Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10, Eur J Biochem, 213, 223, 10.1111/j.1432-1033.1993.tb17752.x · DOI
  52. Pons, 1991, Detection of human hepatitis anti-liver kidney microsomes (LKM2) autoantibodies on rat liver sections is predominantly due to reactivity with rat liver P-450 IIC11, J Pharmacol Exp Ther, 259, 1328, 10.1016/S0022-3565(25)20545-6 · DOI
  53. Leeder, 1996, Epitope mapping studies with human anti-cytochrome P450 3A antibodies, Mol Pharmacol, 49, 234, 10.1016/S0026-895X(25)08704-8 · DOI
  54. Siegmund, 1985, The influence of the acetylator phenotype for the clinical use of dihydralazine, Int J Clin Pharmcol Ther Toxicol, 23, S74
  55. Bourdi, 1992, Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug, Mol Pharmacol, 42, 280, 10.1016/S0026-895X(25)08911-4 · DOI
  56. Rieder, 1991, Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions, Clin Pharmacol Ther, 49, 13, 10.1038/clpt.1991.3 · DOI · Paper page
  57. Nataf, 1986, A new anti-liver microsome antibody: a specific marker of dihydralazine-induced hepatitis [abstract], Gastroenterology, 90, 1751
  58. Leeder, 1992, Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions, J Pharmacol Exp Ther, 263, 360, 10.1016/S0022-3565(25)10348-0 · DOI
  59. Riley, 1993, Human anti-endoplasmic reticulum autoantibodies produced in aromatic anticonvulsant hypersensitivity reactions recognise rodent CYP3A proteins and a similarly regulated human P450 enzyme(s), Biochem Biophys Res Commun, 191, 32, 10.1006/bbrc.1993.1180 · DOI
  60. Leeder, 1998, Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions, Pharmacogenetics, 8, 211, 10.1097/00008571-199806000-00004 · DOI
  61. Gennis, 1991, Familial occurrence of hypersensitivity to phenytoin, Am J Med, 91, 631, 10.1016/0002-9343(91)90216-K · DOI
  62. Bhat, 1998, Minocycline-induced hepatitis with autoimmune features and neutropenia, Clin Gastroenterol, 27, 74, 10.1097/00004836-199807000-00016 · DOI
  63. Goldstein, 2000, Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis, Am J Clin Pathol, 114, 591, 10.1309/KV2J-VX6Q-L95V-VDE4 · DOI
  64. Lawrenson, 2000, Liver damage associated with minocycline use in acne: a systematic review of published literature and pharmacovigilance data, Drug Safety, 23, 333, 10.2165/00002018-200023040-00006 · DOI
  65. Teitelbaum, 1998, Minocycline-related autoimmune hepatitis: case series and literature review, Arch Pediatr Adolesc Med, 152, 1132, 10.1001/archpedi.152.11.1132 · DOI
  66. Angulo, 1998, Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis, Semin Arthritis Rheum, 28, 187, 10.1016/S0049-0172(98)80035-8 · DOI
  67. Herzog, 1997, Study of immune reactivity of minocycline-induced chronic active hepatitis, Dig Dis Sci, 42, 1100, 10.1023/A:1018817926394 · DOI
  68. Scully, 1993, Diclofenac-induced hepatitis: 3 cases with features of autoimmune chronic active hepatitis, Dig Dis Sci, 38, 744, 10.1007/BF01316809 · DOI
  69. Benninger, 1999, Acute hepatitis induced by greater celandine (chelidonium majus), Gastroenterology, 117, 1234, 10.1016/S0016-5085(99)70410-5 · DOI
  70. Berardinis, 2000, Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes, Mol Pharm, 58, 542, 10.1124/mol.58.3.542 · DOI
  71. Hong, 1997, Is melatonin associated with the development of autoimmune hepatitis?, J Clin Gastroenterol, 25, 376, 10.1097/00004836-199707000-00020 · DOI
  72. Kamiyama, 1997, Autoimmune hepatitis triggered by administration of an herbal medicine, Am J Gastroenterol, 92, 703
  73. Al-Kawas, 1981, Allopurinol hepatotoxicity: report of two cases and review of literature, Ann Intern Med, 95, 588, 10.7326/0003-4819-95-5-588 · DOI
  74. Maddrey, 1975, Severe hepatitis from methyldopa, Gastroenterology, 68, 351, 10.1016/S0016-5085(75)80018-7 · DOI
  75. Saggie, 1979, Patterns of hepatic injury by methyldopa, S Afr Med J, 55, 25
  76. Stricker, 1988, Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases, Hepatology, 8, 599, 10.1002/hep.1840080327 · DOI
  77. Marotta, 1998, Pemoline hepatotoxicity in children, J Pediatr, 132, 894, 10.1016/S0022-3476(98)70329-4 · DOI
  78. Moradpour, 1994, Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis, Hepatology, 20, 1437, 10.1002/hep.1840200610 · DOI
  79. Derby, 1993, Erythromycin-associated cholestatic hepatitis, Med J Aust, 158, 600, 10.5694/j.1326-5377.1993.tb137625.x · DOI
  80. O'Donohue, 2000, Co-amoxiclav jaundice: clinical and histological features and HLA Class II association, Gut, 47, 717, 10.1136/gut.47.5.717 · DOI
  81. Tarazi, 1993, Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration, Gastroenterology, 104, 569, 10.1016/0016-5085(93)90428-F · DOI
  82. Nissan, 1996, Captopril-associated pseudochangitis, Arch Surg, 131, 670, 10.1001/archsurg.1996.01430180096021 · DOI
  83. Tholakanahalli, 1998, Glibenclamide-induced cholestasis, West J Med, 168, 274
  84. Larrey, 1989, Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant, Hepatology, 10, 168, 10.1002/hep.1840100208 · DOI
  85. Dujovne, 1967, Sulfonamide hepatic injury, N Engl J Med, 277, 785, 10.1056/NEJM196710122771503 · DOI
  86. Aaron, 1985, Diphenylhydantoin-induced hepatotoxicity, Am J Gastroenterol, 80, 200
  87. Larrey, 1997, Genetic predisposition to drug-induced hepatotoxicity, J Hepatol, 26, 12, 10.1016/S0168-8278(97)80492-8 · DOI
  88. Daly, 1995, Molecular basis of polymorphic drug metabolism, J Mol Med, 73, 539, 10.1007/BF00195139 · DOI
  89. Shear, 1988, Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk, J Clin Invest, 82, 1826, 10.1172/JCI113798 · DOI
  90. Rieder, 1989, Diagnosis of sulfonamide hypersensitivity reactions by in vitro “rechallenge” with hydroxylamine metabolites, Ann Intern Med, 110, 286, 10.7326/0003-4819-110-4-286 · DOI
  91. Hoft, 1981, Halothane hepatitis in three pairs of closely related women, N Engl J Med, 304, 1023, 10.1056/NEJM198104233041707 · DOI
  92. Otsuka, 1985, HLA antigens in patients with unexplained hepatitis following halothane anesthesia, Acta Anaesthesiol, 29, 497, 10.1111/j.1399-6576.1985.tb02242.x · DOI
  93. Berson, 1994, Possible role of HLA in hepatotoxicity: an exploratory study in 71 patients with drug-induced idiosyncratic hepatitis, J Hepatol, 20, 336, 10.1016/S0168-8278(94)80004-9 · DOI
  94. Maria, 1997, Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury, Gut, 41, 534, 10.1136/gut.41.4.534 · DOI

Cited by

Sorted by citations

Metadata

Authors
Liu, Z.-X., & Kaplowitz, N.
Venue
Clinics in Liver Disease
Publisher
Elsevier BV
Published
2002-08
Volume
6
Issue
3
Pages
755-774
ISSN
1089-3261
DOI
10.1016/s1089-3261(02)00025-9
Cited by
170
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review